#1 Clinical Trials Search in Europe

Tumor Necrosis Factor-Alpha

This article discusses a clinical trial investigating the use of 2LEBV® and 2LXFS® to reduce fatigue in patients with Epstein-Barr Virus (EBV) infection. The study aims to compare the effectiveness of these treatments against a placebo in managing fatigue and other EBV-related symptoms. The trial will also examine changes in immune system markers and antibodies throughout the treatment period.

Table of Contents

What is Tumor Necrosis Factor-Alpha?

Tumor Necrosis Factor-Alpha (TNF-α) is a protein that plays a crucial role in our body’s immune system[1]. It’s a type of cytokine, which means it’s a substance that helps cells communicate, especially during immune responses. TNF-α got its name because it was first discovered to be able to kill tumor cells, but we now know it has many other important functions in the body.

Medical Uses of TNF-α

TNF-α is being studied and used in various medical treatments due to its powerful effects on the immune system. Some of its potential uses include:

  • Fighting viral infections
  • Reducing inflammation
  • Helping to regulate immune responses

It’s important to note that while TNF-α can be beneficial, it needs to be carefully controlled. Too much TNF-α in the body can lead to excessive inflammation, which is why some treatments actually aim to block TNF-α in certain autoimmune diseases[1].

TNF-α in Epstein-Barr Virus Treatment

In the context of this clinical trial, TNF-α is being studied as part of a treatment for Epstein-Barr Virus (EBV) infection[1]. EBV is a common virus that can cause various symptoms, including severe fatigue. The researchers are investigating whether a treatment that includes TNF-α, along with other substances, can help reduce fatigue and other symptoms in patients with EBV infection.

How is TNF-α Administered?

In this study, TNF-α is part of a medication called 2LXFS, which is administered as pillules for oromucosal use[1]. This means the medication is designed to be absorbed through the mucous membrane of the mouth. It’s a form of administration that’s different from typical pills that you swallow or injections.

Current Clinical Trial Information

The clinical trial is studying the effectiveness of 2LXFS (which contains TNF-α) in treating fatigue related to EBV infection. Here are some key points about the trial:

  • It’s a randomized, placebo-controlled, double-blind study[1].
  • The main goal is to see if the treatment reduces fatigue severity[1].
  • The study is also looking at other symptoms related to EBV infection and how they change with treatment[1].
  • Participants will be followed for up to 12 months to see long-term effects[1].

Potential Side Effects and Considerations

As with any medical treatment, there may be potential side effects or risks. The clinical trial is designed to monitor for any adverse events. It’s important to note that:

  • The treatment is being tested on patients aged 12 years and older[1].
  • Patients with severe immunodeficiency diseases or those undergoing certain treatments like chemotherapy are excluded from the study[1].
  • The study excludes pregnant or breastfeeding women[1].

Remember, this treatment is still being studied, and more research is needed to fully understand its effects and potential benefits. If you’re interested in this treatment or have concerns about EBV infection, it’s always best to consult with your healthcare provider for personalized advice.

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Medications Tested 2LEBV® and 2LXFS®
Main Condition Epstein-Barr Virus (EBV) infection with fatigue
Primary Outcome Fatigue severity reduction at 6 months
Secondary Outcomes Other EBV symptoms, lymphocyte typing, antibody levels
Participant Age 12 years and older
Treatment Duration 6 months, with follow-up at 3 and 12 months
Key Components Interferon alfa, interleukins, tumor necrosis factor-alpha

FAQ

  • What is the main goal of this clinical trial? The main goal is to compare the effectiveness of 2LEBV® or 2LXFS®/2LEBV® treatment versus placebo in reducing fatigue severity at the end of the treatment period for patients with Epstein-Barr Virus infection.
  • Who can participate in this study? Participants must be 12 years or older, experiencing significant fatigue for at least a month, and have at least two other EBV-related symptoms. They must also have a positive EBV serology test and agree to undergo lymphocyte typing.
  • How long does the treatment last? The treatment period lasts for 6 months, with follow-up visits at 3 months and 12 months to assess long-term effects.
  • What are the medications being tested in this trial? The trial is testing 2LEBV® and 2LXFS®, which contain various substances including interferon alfa, interleukins, and tumor necrosis factor-alpha. These are compared to a placebo.
  • How will the effectiveness of the treatment be measured? The main measure of effectiveness is the general fatigue scale of the MFI-20 questionnaire at the end of the 6-month treatment. Other measures include changes in EBV-related symptoms, lymphocyte typing, and antibody levels.

Ongoing Clinical Trials on Tumor Necrosis Factor-Alpha

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain cancers. It often leads to fatigue and other symptoms.
  • Fatigue: A feeling of tiredness or lack of energy that can be severe and long-lasting, especially in EBV infections.
  • Placebo: A substance with no active medical effects, used as a control in testing new drugs.
  • Serology: A blood test that looks for antibodies in your blood to identify specific infections.
  • Lymphocyte typing: A test that identifies and counts different types of white blood cells (lymphocytes) in the blood.
  • IgG and IgM: Types of antibodies produced by the immune system in response to infections.
  • MFI-20 questionnaire: A tool used to measure different aspects of fatigue, including general fatigue, physical fatigue, and mental fatigue.
  • Tumor Necrosis Factor-Alpha: A substance involved in systemic inflammation and acute phase reaction, which is one of the components in the tested medication.
  • Double-blind study: A study where neither the participants nor the researchers know who is receiving the actual treatment or the placebo.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/